Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences
Open Access
- 26 September 2024
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 84 (10) , 1251-1273
Abstract
Asthma and cardiovascular disease (CVD) often co-exist. When a patient has both conditions, management requires an approach that addresses the unique challenges of each condition separately, while also considering their potential interactions. However, specific guidance on the management of asthma in patients with CVD and on the management of CVD in patients with asthma is still lacking. Nevertheless, health care providers need to adopt a comprehensive approach that includes both respiratory and CVD health. The management of CVD in patients with asthma requires a delicate balance between controlling respiratory symptoms and minimising potential cardiovascular (CV) risks. In the absence of specific guidelines for the management of patients with both conditions, the most prudent approach would be to follow established guidelines for each condition independently. Careful selection of asthma medications is essential to avoid exacerbation of CV symptoms. In addition, optimal management of CV risk factors is essential. However, close monitoring of these patients is important as there is evidence that some asthma medications may have adverse effects on CVD and, conversely, that some CVD medications may worsen asthma symptoms. On the other hand, there is also increasing evidence of the potential beneficial effects of asthma medications on CVD and, conversely, that some CVD medications may reduce the severity of asthma symptoms. We aim to elucidate the potential risks and benefits associated with the use of asthma medications in patients with CVD, and the potential pulmonary risks and benefits for patients with asthma who are prescribed CVD medications.Keywords
Funding Information
- Università degli Studi di Roma Tor Vergata
This publication has 228 references indexed in Scilit:
- Salbutamol inhalation has no effect on myocardial ischaemia, arrhythmias and heart‐rate variability in patients with coronary artery disease plus asthma or chronic obstructive pulmonary diseaseJournal of Internal Medicine, 1998
- Elevation of the plasma histamine concentration in the coronary circulation in patients with variant anginaThe American Journal of Cardiology, 1996
- Angiotensin II potentiates methacholine-induced bronchoconstriction in human airway both in vitro and in vivoEuropean Respiratory Journal, 1995
- Effects of Aerosol Ipratropium Bromide on Cardiac Vagal ToneChest, 1994
- Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitorsBMJ, 1994
- Long-Term Effects of a Long-Acting β2-Adrenoceptor Agonist, Salmeterol, on Airway Hyperresponsiveness in Patients with Mild AsthmaNew England Journal of Medicine, 1992
- Sudden Cardiac Death in Bronchial Asthma, and Inhaled Beta-Adrenergic AgonistsChest, 1992
- The Arrhythmogenicity of TheophyllineChest, 1991
- Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterolThe American Journal of Medicine, 1989
- Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.Circulation Research, 1986